A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children
NCT ID: NCT01091246
Last Updated: 2011-09-26
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
2312 participants
INTERVENTIONAL
2010-03-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Q/LAIV (MEDI3250)
Q/LAIV (quadrivalent live attenuated influenza vaccine) (MEDI3250) was supplied in the Becton Dickinson Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10\^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 temperature sensitive, cold-adapted, attenuated, 6:2 resassortant influenza strains (A/H1N1 \[A/South Dakota/6/2007\], A/H3N2 \[A/Uruguay/716/2007\], B/Victoria \[B/Malaysia/2506/2004\], and B/Yamagata \[B/Florida/4/2006\]).
Q/LAIV (MEDI3250)
10 \^7.0 ± 0.5 FFU/dose of each of 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria
FluMist/B/Yamagata
FluMist/B/Yamagata (trivalent live attenuated influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10\^7.0 ± 0.5 FFU of each of 3 temperature sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 \[South Dakota/6/2007\], A/H3N2 \[A/Uruguay/716/2007\], and B/Yamagata \[B/Florida/4/2006\])
FluMist/B/Yamagata
10 \^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Yamagata
FluMist/B/Victoria
FluMist/B/Victoria (trivalent live attenuated influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10\^7.0 ± 0.5 FFU of each of 3 temperature sensitive, cold-adapted, attenuated, 6:2 reassortant influenza stains (A/H1N1 \[A/South Dakota/6/2007\], A/H3N2 \[A/Uruguay/716/2007\], and B/Victoria \[B/Malaysia/2506/2004\]).
FluMist/B/Victoria
10 \^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Victoria
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Q/LAIV (MEDI3250)
10 \^7.0 ± 0.5 FFU/dose of each of 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria
FluMist/B/Yamagata
10 \^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Yamagata
FluMist/B/Victoria
10 \^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Victoria
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 2 through 17 years at the time of randomization
* Written informed consent and any locally required authorization (eg, HIPAA in the USA, EU Data Privacy Directive in the EU, and written informed assent if applicable) obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations
* Females of childbearing potential, unless surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), has sterile male partner, is premenarchal, or practices abstinence, must have used an effective method of avoiding pregnancy (including oral, transdermal, or implanted contraceptives, intrauterine device, female condom with spermicide, diaphragm with spermicide, cervical cap with spermicide, or use of a condom with spermicide by the sexual partner) for 30 days prior to the first dose of investigational product, and must agree to continue using such precautions for 60 days after the final dose of investigational product
* A subject who is considered by the investigator to be at risk of pregnancy must also have a negative urine pregnancy test at screening and, if screening and Day 0 do not occur on the same day, on the day of vaccination prior to randomization. Investigator judgment is required to assess each subject's need for pregnancy testing
* Healthy by medical history and physical examination OR presence of stable underlying chronic medical condition for which hospitalization has not been required in the previous year
* Able to complete follow-up period of 180 days post last dose of vaccine as required by the protocol
* Subject/legal representative is available by telephone
* Child's legal representative is able to understand and comply with the requirements of the protocol, as judged by the investigator
Exclusion Criteria
* Fever ≥ 100.4°F (38.0°C) at randomization
* History of asthma, or in children \< 5 years of age, history of recurrent wheezing
* Any drug therapy from 15 days prior to randomization or expected drug therapy through 28 days post last dose with the exception of the following classes/types of medications, which are allowed:
* Contraceptives (change in contraceptive type or method is acceptable as long as guidelines are followed for prevention of pregnancy during change);
* Topical corticosteroids, calcineurin inhibitors, or antifungals for uncomplicated dermatitis;
* Chronic medications (including those taken on an as-needed basis) that have been well tolerated and were not initiated and/or did not have a dosage change within 90 days prior to randomization.
* Current or expected receipt of immunosuppressive medications within a 28 day window around any dose, including an immunosuppressive dose of corticosteroids, which is defined as ≥ 20 mg/day of prednisone or its equivalent, given daily or on alternate days for ≥ 15 days) (intranasal, intra-articular, and topical corticosteroids are permitted); Note: topical corticosteroids for uncomplicated dermatitis may be used throughout the study according to the judgment of the investigator; topical calcineurin inhibitors may be used in accordance with their package insert at entry and during study participation
* Receipt of immunoglobulin or blood products within 90 days before randomization into the study or expected receipt during study participation
* Receipt of any investigational drug therapy within 28 days prior to Dose 1 or planned receipt of any investigational drug therapy through 90 days after final dosing of investigational product (use of licensed agents for indications not listed in the package insert is permitted)
* Receipt of any nonstudy vaccine within 28 days prior to randomization or planned receipt of nonstudy vaccine through 28 days after final dosing
* Receipt of any nonstudy seasonal influenza vaccine within 90 days of Dose 1 or planned receipt of nonstudy seasonal influenza vaccine prior to 35 days post last dose of investigational product
* Any known immunosuppressive condition or immune deficiency disease including known or suspected infection with human immunodeficiency virus (HIV)
* History of allergic disease or reactions likely to be exacerbated by any component of the investigational product including allergy to eggs, egg proteins, gentamicin, or gelatin or serious, life threatening, or severe reactions to previous influenza vaccinations
* Use of aspirin or salicylate-containing products within 28 days prior to randomization or expected receipt through 28 days after final vaccination;
* History of Guillain-Barré syndrome
* Use of antiviral agents with activity against influenza virus (including amantadine, rimantadine, oseltamivir, and zanamivir) within 28 days prior to first dose of investigational product or anticipated use of such agents within 28 days after last scheduled vaccination
* Known or suspected mitochondrial encephalomyopathy
* Pregnant or lactating female
* History of alcohol or drug abuse that, in the opinion of the investigator, would affect the subject's safety or compliance with study
* Any condition that, in the opinion of the investigator, might compromise the safety of the subject in the study or would interfere with evaluation of the safety or immunogenicity of the investigational products
* Subject, legal representative, or immediate family member of subject who is an employee of the clinical study site or who is otherwise involved with the conduct of the study
* A history of epilepsy, seizure, or an evolving neurological condition except that of a single febrile seizure that occurred 3 or more years prior to enrollment would not disqualify a subject
Note: an individual who initially is excluded from study participation based on one or more of the above time-limited criteria may be reconsidered for enrollment once the condition has resolved as long as the subject continues to meet all other entry criteria and the same SID number is used
2 Years
17 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MedImmune LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
MedImmune, LLC
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Judith Falloon, M.D.
Role: STUDY_DIRECTOR
MedImmune LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Birmingham, Alabama, United States
Research Site
Mobile, Alabama, United States
Research Site
Tucson, Arizona, United States
Research Site
Benton, Arkansas, United States
Research Site
Bentonville, Arkansas, United States
Research Site
Fayetteville, Arkansas, United States
Research Site
Jonesboro, Arkansas, United States
Research Site
Little Rock, Arkansas, United States
Research Site
Anaheim, California, United States
Research Site
Fountain Valley, California, United States
Research Site
Fresno, California, United States
Research Site
Long Beach, California, United States
Research Site
Paramount, California, United States
Research Site
Sacramento, California, United States
Research Site
San Francisco, California, United States
Research Site
West Covina, California, United States
Research Site
Wilmington, Delaware, United States
Research Site
Boca Raton, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Ponte Vedra, Florida, United States
Research Site
South Miami, Florida, United States
Research Site
St. Petersburg, Florida, United States
Research Site
West Palm Beach, Florida, United States
Research Site
Dalton, Georgia, United States
Research Site
Marietta, Georgia, United States
Research Site
Woodstock, Georgia, United States
Research Site
Chicago, Illinois, United States
Research Site
DeKalb, Illinois, United States
Research Site
Newton, Kansas, United States
Research Site
Overland Park, Kansas, United States
Research Site
Wichita, Kansas, United States
Research Site
Bardstown, Kentucky, United States
Research Site
Lexington, Kentucky, United States
Research Site
Metairie, Louisiana, United States
Research Site
Kalamazoo, Michigan, United States
Research Site
Niles, Michigan, United States
Research Site
Stevensville, Michigan, United States
Research Site
Plymouth, Minnesota, United States
Research Site
Saint Paul, Minnesota, United States
Research Site
Kansas City, Missouri, United States
Research Site
St Louis, Missouri, United States
Research Site
St Louis, Missouri, United States
Research Site
Omaha, Nebraska, United States
Research Site
Omaha, Nebraska, United States
Research Site
Papillion, Nebraska, United States
Research Site
Las Vegas, Nevada, United States
Research Site
Lebanon, New Hampshire, United States
Research Site
Albuquerque, New Mexico, United States
Research Site
Binghamton, New York, United States
Research Site
Brooklyn, New York, United States
Research Site
Mineola, New York, United States
Research Site
Rochester, New York, United States
Research Site
Rochester, New York, United States
Research Site
Asheboro, North Carolina, United States
Research Site
Boone, North Carolina, United States
Research Site
Clyde, North Carolina, United States
Research Site
Mt Pleasant, North Carolina, United States
Research Site
Raleigh, North Carolina, United States
Research Site
Raleigh, North Carolina, United States
Research Site
Winston-Salem, North Carolina, United States
Research Site
Bismarck, North Dakota, United States
Research Site
Fargo, North Dakota, United States
Research Site
Akron, Ohio, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Dayton, Ohio, United States
Research Site
Huber Heights, Ohio, United States
Research Site
Norman, Oklahoma, United States
Research Site
Yukon, Oklahoma, United States
Research Site
Altoona, Pennsylvania, United States
Research Site
Erie, Pennsylvania, United States
Research Site
Greenville, Pennsylvania, United States
Research Site
Harleysville, Pennsylvania, United States
Research Site
Hermitage, Pennsylvania, United States
Research Site
Latrobe, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Scotland, Pennsylvania, United States
Research Site
Sellersville, Pennsylvania, United States
Research Site
Charleston, South Carolina, United States
Research Site
Charleston, South Carolina, United States
Research Site
Mt. Pleasant, South Carolina, United States
Research Site
Bristol, Tennessee, United States
Research Site
Clarksville, Tennessee, United States
Research Site
Kingsport, Tennessee, United States
Research Site
Nashville, Tennessee, United States
Research Site
Arlington, Texas, United States
Research Site
Fort Worth, Texas, United States
Research Site
Fort Worth, Texas, United States
Research Site
Longview, Texas, United States
Research Site
New Branfels, Texas, United States
Research Site
Sugarland, Texas, United States
Research Site
Draper, Utah, United States
Research Site
Layton, Utah, United States
Research Site
Orem, Utah, United States
Research Site
Roy, Utah, United States
Research Site
Salt Lake City, Utah, United States
Research Site
South Jordan, Utah, United States
Research Site
Syracuse, Utah, United States
Research Site
Burke, Virginia, United States
Research Site
Charlottesville, Virginia, United States
Research Site
Vienna, Virginia, United States
Research Site
Virginia Beach, Virginia, United States
Research Site
Huntington, West Virginia, United States
Research Site
Franklin, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MI-CP208
Identifier Type: -
Identifier Source: org_study_id